2017 Mo-99 Topical Meeting on
Molybdenum-99 Production Technology Development

September 10-13, 2017
Montreal Marriott Chateau Champlain
Montreal, QC Canada

Coquí RadioPharmaceuticals Corp.

Carmen I. Bigles
Coquí Pharma
1172 South Dixie Hwy. #335
Coral Gables, FL 33146

COQUÍ PHARMA (COQUÍ) IS IN THE PROCESS OF LICENSING AND BUILDING A DEDICATED MEDICAL ISOTOPE PRODUCTION FACILITY (MIPF). THIS MIPF WILL BE THE FIRST SUCH FACILITY IN THE UNITED STATES AND IS DESIGNED TO CREATE A COMMERCIALLY SCALABLE AND RELIABLE SOURCE OF MEDICAL DIAGNOSTIC AND THERAPEUTIC RADIOISOTOPES. COQUÍ'S FACILITY WILL PRODUCE MOLYBDENUM-99 (MO-99). THIS CRITICAL MATERIAL IS THE WORLD'S MOST WIDELY USED MEDICAL RADIOISOTOPE, UTILIZED IN 80% OF ALL NUCLEAR MEDICINE PROCEDURES. ANNUALLY OVER 18 MILLION PROCEDURES IN THE UNITED STATES UTILIZE MO-99. THERE IS CURRENTLY NO DOMESTIC PRODUCTION SOURCE FOR THIS MATERIAL.

COQUÍ'S FOUNDERS, MANAGEMENT TEAM AND EXPERIENCED BOARD OF DIRECTORS HAVE RECOGNIZED AN ONGOING AND DEEPENING SUPPLY SHORTAGE FOR MO-99 DRIVEN BY AGING FOREIGN NUCLEAR REACTORS WHICH CURRENTLY REPRESENT THE ONLY SOURCE OF MO-99. COQUÍ WILL LICENSE AND BUILD A MIPF IN OAK RIDGE, TN THAT CONSISTS OF TWIN RESEARCH-LEVEL SMALL NUCLEAR REACTORS, BASED ON A PROVEN AND TURNKEY PROJECT DELIVERED BY INVAP, THE WORLD'S LEADING DESIGNER OF RESEARCH NUCLEAR REACTORS AND MO-99 PRODUCTION FACILITIES.